Sella Nicolò, Pettenuzzo Tommaso, Della Paolera Michele, Andreatta Giulio, Boscolo Annalisa, De Cassai Alessandro, Muraro Luisa, Peralta Arianna, Persona Paolo, Petranzan Enrico, Zarantonello Francesco, Serra Eugenio, Navalesi Paolo
Department of Medicine (DIMED), Padua University School of Medicine, Italy.
Anesthesia and Intensive Care Unit, Padua University Hospital, Italy.
Case Rep Crit Care. 2021 Jul 9;2021:2032197. doi: 10.1155/2021/2032197. eCollection 2021.
Veno-venous extracorporeal membrane oxygenation (V-V ECMO) may be required to treat critically ill patients with COVID-19-associated severe acute respiratory distress syndrome (ARDS). We report the case of a 43-year-old peripartum patient, who underwent two sequential V-V ECMO runs. The first extracorporeal support was established for COVID-19 ARDS, as characterized by severe hypoxemia and hypercapnia (arterial partial pressure of oxygen to inspired oxygen fraction ratio 85 mmHg and arterial partial pressure of carbon dioxide 95 mmHg) and reduction of respiratory system static compliance to 25 mL/cmHO, unresponsive to mechanical ventilation and prone positioning. After 22 days of lung rest, V-V ECMO was successfully removed and ventilator weaning initiated. A second V-V ECMO was required 7 days later, because of newly onset ARDS due to Pseudomonas aeruginosa ventilator-associated pneumonia. The second V-V ECMO run lasted 12 days. During both V-V ECMO runs, anticoagulation and ventilator settings were titrated through bedside thromboelastometry and electrical impedance tomography, respectively, without major complications. The patient was successfully decannulated, weaned from mechanical ventilation, and finally discharged home without oxygen therapy. At one-month follow-up, she showed good general conditions and no sign of respiratory failure.
对于患有新型冠状病毒肺炎相关严重急性呼吸窘迫综合征(ARDS)的危重症患者,可能需要采用静脉-静脉体外膜肺氧合(V-V ECMO)进行治疗。我们报告了一例43岁的围产期患者,该患者先后接受了两次V-V ECMO治疗。首次体外支持是针对新型冠状病毒肺炎ARDS建立的,其特征为严重低氧血症和高碳酸血症(动脉血氧分压与吸入氧分数比为85 mmHg,动脉二氧化碳分压为95 mmHg),呼吸系统静态顺应性降至25 mL/cmH₂O,对机械通气和俯卧位通气无反应。经过22天的肺休息后,成功撤除V-V ECMO并开始撤机。7天后,由于铜绿假单胞菌呼吸机相关性肺炎导致新发ARDS,需要再次进行V-V ECMO治疗。第二次V-V ECMO治疗持续了12天。在两次V-V ECMO治疗期间,分别通过床旁血栓弹力图和电阻抗断层扫描调整抗凝和呼吸机设置,未出现重大并发症。患者成功拔管,撤机,最终无需吸氧治疗出院。在1个月的随访中,她的一般状况良好,无呼吸衰竭迹象。